Clinical Trial Update: Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a two-arm regimen for relapsed or refractory multiple myeloma using daratumumab, bortezomib, and dexamethasone followed by daratumumab,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (Velcade) (Bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Daratumumab (Darzalex) (daratumumab)
• Ixazomib (Ninlaro) (Ixazomib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 2 | Status: ACTIVE_NOT_RECRUITING